Clinical Trial

UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 8, 2021 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To explore whether the application of irinotecan under the guidance of UGT1A1 gene in neoadjuvant chemotherapy and radiotherapy for locally advanced rectal cancer could improve the clinical efficacy in the real world.
Trial Details
NCT Number NCT05148767
Lead Sponsor Zhejiang Cancer Hospital
Conditions Rectal Cancer Stage III
Enrollment 606 participants
Start Date 2022-01-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2021-12-08